Partners
CereVasc
CereVasc, Inc., is a clinical-stage, venture-funded, medical device company developing novel, minimally invasive treatments for patients with neurological diseases. Its flagship product, the eShunt® System, is a percutaneous endovascular catheter that accesses CSF at the base of the brain, anterior to the pons/brainstem via a minimally invasive approach. Presently in clinical trials to deploy an implant into the CSF, the system has been designed to offer the first minimally invasive treatment for hydrocephalus. Encouraging trial data supports the potential alternative use of the device for CNS therapy delivery, focused on balancing invasiveness and efficiency versus existing ROAs.
ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the US and expanding into the EU. The SmartFlow® cannula is being used in partnership with over 20 biologics & drug delivery companies in various stages from preclinical research to late stage regulatory trials. More than 4,000 cases have been supported by our field-based clinical specialist team which offers support and services for our partners.
Neurochase
Our mission is to accelerate the development and commercialization of innovative therapeutics for the central nervous system (CNS) by building the next-generation of universally accessible interventional engineering tools for functional neurosurgery.
Beacon Targeted Therapies
We are a clinical trial and pipeline database solution designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth, and real-time information in the rapidly evolving drug development landscape. For more information or to request a demo, visit our website.
Gubra
Founded in 2008, we are a privately-held biotech company. We work with big pharma, biotech and academia across the world. Through a constant focus on high quality data, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.
To study gene delivery or biodistribution in pre-clinical models of neurodegeneration, we have developed a unique pipeline for quantitative whole-brain 3D imaging. By combining light sheet microscopy, AI-powered image analysis and cloud-based data reporting we enable visualisation and quantification of CNS targets, drug distribution and viral uptake across the intact mouse brain.
If you offer any services or products which could support this audience of industry experts,
please get in touch.